Keywords: Pfizer, Sutent, Bayer, Onyx, Nexavar, Live cancer

Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer’s Nexavar

Article | 26 April 2010

Print This

In another setback to extend the indications of its cancer drug Sutent (sunitinib), global drug behemoth Pfizer has announced the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in